Slideshow: Examining Preferences and Attitudes Around OTC Naloxone
The first nonprescription, OTC naloxone nasal spray (Narcan) was approved by the FDA in March 2023.
As opioid overdose rates continue to climb, access to OTC naloxone through local pharmacies is more important than ever. At the American Pharmacists Association 2024 Annual Meeting and Exposition, held in Orlando, Florida, from March 22 to 25, several posters examined the attitudes and preferences prevalent around OTC naloxone access in the pharmacy.
Read more of our coverage from the 2024 APhA Annual Meeting & Exposition here
References
1. Rodríguez A, Carter C, Glven A, Contreras AU, Hohmann L. A national cross-sectional survey of consumers’ comfort and purchase intentions regarding over-the-counter (OTC) naloxone. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1315.
2. AlMahasis S, Maurer MM. Development and implementation of best practice alert (BPA) for naloxone prescribing at rural community pharmacies in Wisconsin: a pilot study. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1323.
3. Marley GT, Shubel C, Gamble AE, Annis I, et al. Naloxone accessibility by standing order in North Carolina community pharmacies. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1327.
4. Glven A, Carter C, Rodríguez A, Contreras AU, Hohmann L. US consumers’ perceived barriers, access, and preferences surrounding over the counter (OTC) naloxone: A national cross-sectional survey. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1329.
Recent Videos
Related Content
